A method treats patient with treatment resistant depression, adjunct to standard antidepressant treatment or as monotherapy. These patients will be identified by non-response to at least one pharmacological antidepressant treatment with a sufficient dose and over a sufficient period of time. Further, one embodiment of the method includes a procedure to identify patients who would benefit from a combination of standard antidepressants with the described compounds from the start of the treatment in order to maximize the likelihood of response. Another embodiment of the method combines the described compounds with forms of Magnesium salts in order to overcome longer term tolerability issues with the compounds. An important downstream mechanism of the described interventions is the property to reduce the production and or increase the absorption of cerebrospinal fluid to treat a variety of symptoms, including cognitive dysfunction, memory loss, apathy, sleep disturbances, pain disorders, and somatoform pain and headache.

The present invention relates generally to the identification of subjects with a predisposition to recurrent depression, predicting a subject's responsiveness to therapy, and determining whether a subject has remitted from depression following therapy. In particular, provided herein are biomarkers, methods, and kits for such uses.

A BDNF quantitative immunochromatographic test strip and its preparation method, comprises: a substrate and a coated film, on which a sample pad, a coated line area and a water-absorbing pad are arranged; the coated line area comprises a marking line, a detecting line and quality control line, which are arranged in parallel and separated from each other, the marking line is arranged close to the sample pad, the detecting line is arranged between the marking line and the quality control line, the quality control line is arranged close to the water-absorbing pad; the marking line is the marking line coated with fluorescent microspheres marked with first BDNF monoclonal antibody and quality control antigen or antibody, the quality control line is the quality control line coated with quality control antibody or antigen, and the detection line is the detection line coated with second BDNF monoclonal antibody.

The present invention is directed to methods of probiotic selection and use based on the capability of microbial biogenic amine uptake as a method for targeted clinical and veterinary applications, including promoting health and well-being and/or treating therapeutic conditions. The present invention utilizes a microbially-focused approach for the development of drug selection and/or probiotic administration in a variety of diseases and disorders.

An embodiment of the present invention provides a novel method for diagnosing, treating, or preventing a mood disorder. The method includes the step of measuring, by using a fusion protein, a level of the anti-fusion protein antibody in a biological sample.

The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.

The present invention relates to new biomarkers and new sets of biomarkers for diagnosing a mood disorder, preferably depression or monitoring the effectiveness of therapy for said mood disorder.

An objective biomarker is capable of evaluating the severity of depression and is clinically useful. The biomarker is used for evaluating the severity of depression, and includes at least one compound selected from the group made of 4-aminobutyric acid ( (gamma)-aminobutyric acid: GABA), arginine, argininosuccinate, isoleucine, indole carboxaldehyde, potassium indoleacetate, carnitine, acetylcarnitine, ornithine, xanthurenate, kynurenate, kynurenine, citrate, creatine, creatinine, glutamine, dimethylglycine, serotonin, taurine, trimethyloxamine (TMAO), tryptophan, norvaline, 3-hydroxybutyrate, phenylalanine, proline, betaine, and lysine.

Compositions and methods for the identification of agents useful for the treatment of neurological disorders, including schizophrenia, are provided.

Provided herein are compositions, kits, and methods for the identification of depressive disorders. In particular, provided herein are compositions, kits, and methods for the detection or diagnosis of major depressive disorder.